About

About Mabion S.A. Mabion, a fully integrated CDMO located in central Europe, was established in 2007 to develop and support the development of protein-based biotherapeutics, including monoclonal antibodies, vaccine antigens and other large proteins. With 17 years of experience, Mabion offers an ‘end-to-end solution, covering all stages of biologic drug development: from early clone selection and small-scale manufacturing through process scale-up, bioanalytical testing, large-scale manufacturing to sterile fill-finish, packaging and serialization. With broad capabilities and well-qualified, experienced staff, Mabion is a perfect long-term partner for any project involving therapeutic proteins, whether your product is in pre-clinical or clinical development or already commercially available. About Mabion S.A. Mabion, a fully integrated CDMO located in central Europe, was established in 2007 to develop and support the development of protein-based biotherapeutics, including monoclonal antibodies, vaccine antigens and other large proteins. With 17 years of experience, Mabion offers an ‘end-to-end solution, covering all stages of biologic drug development: from early clone selection and small-scale manufacturing through process scale-up, bioanalytical testing, large-scale manufacturing to sterile fill-finish, packaging and serialization. With broad capabilities and well-qualified, experienced staff, Mabion is a perfect long-term partner for any project involving therapeutic proteins, whether your product is in pre-clinical or clinical development or already commercially available. Mabion is a fully integrated CDMO offering a wide services associated with the development and GMP manufacturing of biotherapeutics, including monoclonal antibodies and any recombinant protein-based products. We offers an end-to-end solution, covering all stages of biologic drug development from CLD through process scale-up and analytics to sterile fill-finish and QC release. Mabion is of the most suitable solution for customers who have recombinant protein-based products in their portfolio, manufactured using mammalian cell line culture technology. Our facilities located in central Poland, which operate in full compliance with GMP, GLP, GCP and ISO principles, can run small- and large-scale manufacturing of biotherapeutics, providing the customers with high-quality products at optimal efficiency and competitive pricing.